Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : eShare Technolgies (ESHR) -- Ignore unavailable to you. Want to Upgrade?

To: Tom Hua who wrote (101)	12/15/1999 11:04:00 PM
From: wily	Read Replies (1) \| Respond to of 653

>>wily, that's wrong. Please show me where you got that figure. The old eShare had revenue of 2.5 million last quarter. For comparison, EGAN had 1.3 MM. Please consult the last 10Q or quarterly results press release, and/or the CC.<< OK. I must have missed where they said "thousands". >>The current chart reflects the old Melita and the new eShare<< I found one now. The first two I looked at only went back to October. Can you explain the weakness since July? >>As for large ownership by management, it's actually viewed positively.<< Are you saying for stocks in general or for this one in particular? Could you explain a little? Thanks for your help Tom, wily

To: Tom Hua who wrote (101)	12/15/1999 11:14:00 PM
From: Integral	Read Replies (1) \| Respond to of 653

Tom, I appreciate your analysis of this company. There is no doubt that it is enormously undervalued relative to KANA and EGAN. There is a good chance that the valuations will converge over time. That said, I'm less clear that this convergence won't occur by the overpriced stocks falling to reasonable valuations rather than by ESHR rising to unreasonable valuations. In absolute terms, it's harder to argue that ESHR is undervalued (although I would certainly like to hear such an argument). In a less volatile market, I might prefer a strategy of off-setting a long position in ESHR by a short position in, say, KANA. Have you considered this alternative? It suffers from the obvious deficiency that overvalued stocks seem to get more and more overvalued in this market.